Adma Biologics, Inc.
ADMA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001368514
No open-market purchases or sales by Adma Biologics, Inc. insiders were filed in the last 90 days; 322 institutions reported holding it in 13F filings for Q2 2026, worth $1.72B in total; superinvestors Duquesne Family Office and Fundsmith hold it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −34 vs. previous quarter
- 322
- 13F valueReported value at the end of Q2 2026
- $1.72B
- Superinvestors holdingAt the end of Q2 2026
- 2
Price chart
Superinvestors holding ADMA, Q2 2026
2 superinvestors report holding Adma Biologics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Duquesne Family Office
Stanley Druckenmiller
0.5%
Adma Biologics, Inc.'s share of the portfolio
- Shares
- 2,784,110
- Value
- $23.3M
Latest insider trades
Open-market purchases and sales by Adma Biologics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 28, 2026 (view filing) | May 27 | 1 day | Grossman Jerrold BDirector | PPurchase | +6.40K | $7.91 | +$50.6K | +1.2%520.3K after | |
| May 14, 2026 (view filing) | May 12 | 2 days | Grossman Jerrold BDirector | PPurchase | +12.5K | $8.01 | +$100.1K | +2.5%513.9K after | |
| May 12, 2026 (view filing) | May 11 | 1 day | Grossman Jerrold BDirector | PPurchase | +12.5K | $8.01 | +$100.1K | +2.6%501.4K after | |
| Mar 17, 2026 (view filing) | Mar 16 | 1 day | Grossman Adam SPresident and CEO | SSale | −21.0K | $15.16 | −$318.4K | −1.0%2.11M after | 2 lots10b5-1 |
| Mar 10, 2026 (view filing) | Mar 9 | 1 day | Kestenberg-Messina Kaitlin M.COO and SVP, Compliance | SSale | −10.1K | $15.63 | −$157.8K | −2.1%466.6K after | |
| Mar 9, 2026 (view filing) | Mar 5-6 | 4 days | Elms SteveDirector | PPurchase | +14.0K | $15.53 | +$217.4K | +0.7%2.05M after | 2 lots |
| Feb 17, 2026 (view filing) | Feb 17 | Same day | Grossman Adam SPresident and CEO | SSale | −21.0K | $16.08 | −$337.7K | −0.9%2.28M after | 2 lots10b5-1 |
| Dec 16, 2025 (view filing) | Dec 15 | 1 day | Grossman Adam SPresident and CEO | SSale | −21.0K | $19.79 | −$415.6K | −1.0%2.01M after | 2 lots10b5-1 |
| Nov 21, 2025 (view filing) | Nov 19 | 2 days | Grossman Adam SPresident and CEO | SSale | −21.0K | $16.00 | −$336.0K | −1.0%2.01M after | 2 lots10b5-1 |
| Oct 24, 2025 (view filing) | Oct 24 | Same day | Grossman Adam SPresident and CEO | SSale | −21.0K | $16.00 | −$336.0K | −1.0%2.02M after | 2 lots10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Adma Biologics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 38,355,684 | $321.0M | 0.00% | +1,524,910+4.1% | Added |
| State Street Corp | 17,116,022 | $143.3M | 0.00% | +3,031,817+21.5% | Added |
| Vanguard Capital Management LLC | 10,103,809 | $84.6M | 0.00% | −203,062−2.0% | Reduced |
| Vanguard Portfolio Management LLC | 10,088,490 | $84.4M | 0.00% | +1,219,833+13.8% | Added |
| Rubric Capital Management LP | 9,339,414 | $78.2M | 0.72% | +7,530,006+416.2% | Added |
| Capital Research Global Investors | 8,756,374 | $73.3M | 0.01% | −2,434,742−21.8% | Reduced |
| First Trust Advisors LP | 7,798,351 | $65.3M | 0.04% | +7,438,134+2,064.9% | Added |
| Geode Capital Management, LLC | 6,059,984 | $50.7M | 0.00% | +235,868+4.0% | Added |
| Caligan Partners LP | 5,725,007 | $47.9M | 2.31% | +968,496+20.4% | Added |
| D. E. Shaw & Co., Inc. | 5,274,597 | $44.1M | 0.03% | +4,713,770+840.5% | Added |